Fig. 1
MG1363-pMG36e-GLP-1 improved cognitive ability in AD mice and motor function in PD mice. a The time schedule to explain the design of the whole experimental design. b The escape latency of mice in the Barnes maze test during the acquisition phase (1–10 days). c The escape latency of mice in the Barnes maze test on the last day. MG1363-pMG36e-GLP-1 had greatly reduced the escape latency. d MG1363-pMG36e-GLP-1 improved the bradykinesia mice induced by MPTP (pole test). e MG1363-pMG36e-GLP-1 increased the distance in the central area moved for PD mice (open-field test). f MG1363-pMG36e-GLP-1 increased the average movement speed for PD mice (open-field test). g MG1363-pMG36e-GLP-1 increased the duration of movement in the central area for PD mice (open-field test). C, control group (n = 8); AD, LPS group (n = 5); AD-G, LPS + 109 CFU MG1363-pMG36e-GLP-1 group (n = 5); PD, MPTP group (n = 8); PD-G, MPTP + 109 CFU MG1363-pMG36e-GLP-1 group (n = 8). Data are presented as mean ± SD. *p < 0.05, **p < 0.01